Completed PHASE1/PHASE2 NCT00088556

Carboplatin, Paclitaxel and TLK286 (Telcyta) as First-Line Therapy in Advanced Non-Small Cell Lung Cancer

Phase 1-2a Dose-Ranging Study of the Triplet Combination of Carboplatin, Paclitaxel and TLK286 as First-Line Therapy in Advanced Non-Small Cell Lung Cancer

Sponsor: Telik

Conditions Carcinoma, Non-Small-Cell Lung

Interventions TLK286 carboplatin paclitaxel

Updated 7 times since 2017 Last updated: May 30, 2012 Started: Aug 31, 2004 Primary completion: May 31, 2009 Completion: May 31, 2009

Listed as NCT00088556, this PHASE1/PHASE2 trial focuses on Carcinoma, Non-Small-Cell Lung and remains completed. Sponsored by Telik, it has been updated 7 times since 2004, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE1/PHASE2
Sep 2024 — Sep 2025 [monthly]

Completed PHASE1/PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1/PHASE2

Phase: PHASE1_PHASE2 → PHASE1/PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1_PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1_PHASE2

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Completed PHASE1_PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE1_PHASE2

First recorded

Aug 2004

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Telik

Data source: Telik

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Baltimore, United States , Bethesda, United States , Boston, United States , Clarksville, United States , Concord, United States , Crystal River, United States , Dallas, United States , Danville, United States , Escondido, United States , Fargo, United States and 27 more locations